Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2000

View Archived Issues

Prous Science presents: Case Histories of Drug Discovery

Company Profile: Siga

PAX9 gene mutation results in missing teeth

Delayed treatment with AM-36 reduces neuronal damage in stroke model

CV Therapeutics establishes Tangier drug discovery program

Addition of infliximab to methotrexate therapy reduces RA symptoms

Compounds and methods for treating or preventing HIV infection and AIDS

Japanese investigators prepare new agents for influenza

Novel Pfizer compounds useful for hyperproliferative disorders

Inhibitors of calmodulin-dependent PDE discovered at Daiichi

AstraZeneca presents new series of insulin sensitizers

Peptides binding to GRP receptors useful for diagnosis, treatment of certain tumors

Novel cis-cyclopropanes from BMS act as melatonin agonists

Cambridge NeuroScience and Algos enter pain management agreement

Maxamine granted orphan drug status for AML

Condensed heterocycles and ester prodrugs as potent antiplatelet, antithrombotic agents

Medarex enters cataract and cancer partnership with Scil Biomedicals

RWJ-67657 undergoes further study based on favorable preliminary biological profile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...